"As required by the bipartisan FDA Food Safety Modernization Act (FSMA), the U.S. Food and Drug Administration today proposed a rule that would require the largest food businesses in the United States and abroad to take steps to prevent facilities"...
In the event of fat overload during therapy, stop the infusion of Liposyn III (intravenous fat emulsion) until visual inspection of the plasma, determination of triglyceride concentrations, or measurement of plasma light-scattering activity by nephelometry indicates the lipid has cleared. Re-evaluate the patient and institute appropriate corrective measures. See WARNINGS and PRECAUTIONS.
The administration of Liposyn III (intravenous fat emulsion) (intravenous fat emulsion) is contraindicated in patients demonstrating disturbances in normal fat metabolism such as pathologic hyperlipemia, lipoid nephrosis or acute pancreatitis if accompanied by hyperlipemia.
With the exception of heparin at 1 to 2 units/mL of fat emulsion, additives to the Liposyn III (intravenous fat emulsion) bottle are contraindicated.
Partly used containers must not be stored for later use. Filters must not be used with Liposyn III (intravenous fat emulsion) . Do not use any bottle in which there appears to be an oiling out of the emulsion.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 2/2/2009
Additional Liposyn III Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Weight Loss Wisdom
Get tips, recipes and inspiration.